🔗 Share this article

While the United States undertakes historic changes to its vaccination guidelines, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccinations in the global health crisis and has concentrated on potential deaths after Covid vaccination in her short time at the Food and Drug Administration.

Proposed Changes to Pediatric Immunization Program

Public health authorities planned to unveil sweeping changes to the childhood immunization program in December, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would put the US at odds with much of the global community with little proof for public health gain. This reveal has been delayed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to speak at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the office this year.

Consolidating Power at the FDA

Høeg's temporary position could signify a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for halting certain pediatric vaccine recommendations in the US in order to be more similar to Denmark's approach, a country with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccination policy – usually the purview of Dr. Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Expertise

Høeg has no obvious experience in medication creation, oversight or management, which has been customary for past heads of the biologics center. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in leading a sizeable institution. She lacks background in drug approvals.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that previous people who led CBER have had.”

This division has an immense range of responsibilities at the agency, the former commissioner emphasized.

“Everybody just focuses on the new drug program, but the generic program clears thousands of generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and all of those must be managed,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant administrative component to the role, which oversees in excess of 5,000 personnel. “It’s a massive leadership role, if you do it right,” she added.

Response and Contentious Initiatives

Regarding inquiries about Høeg’s fitness for the role and whether this assignment signifies greater collaboration among regulatory chiefs on vaccines, a press secretary stated that the “questions stem from flawed premises”.

“Her experience is consistent with the functions of her job,” the official said, citing the months Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a contentious expedited medication authorization process that apparently worried her preceding directors. “By what process are these drugs being picked for this fast-track system? Who makes the decisions?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the agency right now.”

Overall, he said, “the agency seems to be moving towards less stringent rules of pharmaceuticals, aside from vaccines.”

Established History on Vaccines

With immunizations, Høeg has a clearer, if concerning, history, some experts have noted. She authored a study using unconfirmed crowd-sourced reports to determine the incidence of myocarditis following Covid vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccinations are riskier than they are.

Among her “desired changes” for the incoming federal leadership included revising regulations for new vaccines and halting “optional” vaccines, she remarked post-election on a audio program. At the agency, Dr. Høeg has allegedly proposed excluding teenage boys from obtaining COVID-19 vaccines.

“She’s an all-around ideologue who begins with her preconceived notions and tailors the evidence to retrofit the evidence in a highly misleading, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|